XOMA Royalty Corporation (XOMA)
NASDAQ: XOMA · Real-Time Price · USD
29.91
-1.22 (-3.92%)
Dec 5, 2025, 4:00 PM EST - Market closed
XOMA Royalty Revenue
XOMA Royalty had revenue of $9.35M in the quarter ending September 30, 2025, with 29.93% growth. This brings the company's revenue in the last twelve months to $47.11M, up 118.02% year-over-year. In the year 2024, XOMA Royalty had annual revenue of $28.49M with 498.72% growth.
Revenue (ttm)
$47.11M
Revenue Growth
+118.02%
P/S Ratio
7.62
Revenue / Employee
$3,623,538
Employees
13
Market Cap
370.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.49M | 23.73M | 498.72% |
| Dec 31, 2023 | 4.76M | -1.27M | -21.06% |
| Dec 31, 2022 | 6.03M | -32.13M | -84.21% |
| Dec 31, 2021 | 38.16M | 8.78M | 29.86% |
| Dec 31, 2020 | 29.39M | 11.02M | 59.96% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
XOMA News
- 1 day ago - XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc - GlobeNewsWire
- 2 days ago - Mural Oncology Announces Sanction of the Scheme by the High Court - GlobeNewsWire
- 15 days ago - XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. - GlobeNewsWire
- 24 days ago - XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewsWire
- 7 weeks ago - XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement - GlobeNewsWire
- 2 months ago - XOMA Royalty PFD Update: Going Back To My Original Sell Ratings - Seeking Alpha
- 2 months ago - XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. - GlobeNewsWire
- 2 months ago - ESSA Pharma Inc. Amends Agreement with XenoTherapeutics - PRNewsWire